Samchundang Pharmaceutical Completes Reorganization of Global Patent Rights Structure for "S-PASS"
"Change of PCT Applicant and Reorganization of Patent Rights in Taiwan"
"Unification of IP System for Global Commercialization and Licensing Negotiations"
Samchundang Pharmaceutical announced on May 21 that it has completed the process of changing the applicant for the PCT (Patent Cooperation Treaty) international patent application related to its oral drug delivery platform "S-PASS," as well as reorganizing the patent rights structure in Taiwan.
According to the company, these procedures were measures taken to expand the global business of the S-PASS platform and to unify its intellectual property (IP) management system.
S-PASS is an oral drug delivery platform technology currently being developed by Samchundang Pharmaceutical. The goal is to convert existing injection-based biopharmaceuticals into oral formulations.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from Samchundang Pharmaceutical stated, "This reorganization of the rights structure is part of the process of systematizing our IP portfolio in line with our global commercialization and licensing strategy," adding, "Going forward, we plan to promote research and development as well as global commercialization based on the S-PASS platform in a step-by-step manner."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.